Since the creation of the company, GENFIT has demonstrated its capacity to outlicense innovative programmes to pharma groups. Our commitment to results-driven alliance management is underpinned by flexibility, communication and transparency at every step of the process.
Partnering is in our genes
Our comprehensive research programmes are aimed at the selection and optimization of innovative lead compounds via therapeutic target identification and validation. Pharma companies recognise the scientific vision, original technological developments and real innovation that we bring to the drug discovery process. Partner programmes arise from GENFIT's proprietary innovation.
Partners appreciate GENFIT's commitment to close collaboration and dedicated alliance management, ensuring that the programmes deliver timely results. All partnerships are undertaken with tightly-knit management procedures, IP protection and protocols in place. This rigorous organisation allows every step of the programme to be closely monitored, results reported and rapid joint decisions to be taken on the next steps in the project.
GENFIT’s wide-ranging knowledge of the pharmaceutical industry and its requirements have led us to implement a highly flexible partnering structure, which adheres to the four principles listed below:
PLAN: Understanding the objectives and expectations of the pharma partner, defining key steps and objectives, role definition and task sharing
ADAPT: Optimal flexibility and modular in-house structure to adapt to programme changes according to strategic, scientific and market developments
SHARE: Mutual co-operation and transparency at every stage of the programme, including the exchange of resources, technological tools, skills, knowledge and information
DELIVER: Performance driven with clearly set deliverables: Commitment to rigorous process management ensures that progress is monitored and reviewed, enabling objectives and deadlines to be met on time, which results in collaborations being renewed
